CA3129008A1 - Compositions comprising 15-hepe and methods of using the same - Google Patents

Compositions comprising 15-hepe and methods of using the same

Info

Publication number
CA3129008A1
CA3129008A1 CA3129008A CA3129008A CA3129008A1 CA 3129008 A1 CA3129008 A1 CA 3129008A1 CA 3129008 A CA3129008 A CA 3129008A CA 3129008 A CA3129008 A CA 3129008A CA 3129008 A1 CA3129008 A1 CA 3129008A1
Authority
CA
Canada
Prior art keywords
hepe
composition
subject
pharmaceutically acceptable
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129008A
Other languages
English (en)
Inventor
David Coughlan
John Climax
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Afimmune Ltd
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of CA3129008A1 publication Critical patent/CA3129008A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3129008A 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same Pending CA3129008A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269280P 2015-12-18 2015-12-18
US62/269,280 2015-12-18
CA3008774A CA3008774C (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3008774A Division CA3008774C (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Publications (1)

Publication Number Publication Date
CA3129008A1 true CA3129008A1 (en) 2017-06-22

Family

ID=57995240

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3129008A Pending CA3129008A1 (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same
CA3008774A Active CA3008774C (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3008774A Active CA3008774C (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Country Status (18)

Country Link
US (5) US9855238B2 (enExample)
EP (2) EP3389647B1 (enExample)
JP (4) JP2018537513A (enExample)
KR (6) KR20180094516A (enExample)
CN (2) CN108697680A (enExample)
AR (2) AR107143A1 (enExample)
AU (4) AU2016370626B2 (enExample)
BR (1) BR122023026625A2 (enExample)
CA (2) CA3129008A1 (enExample)
ES (1) ES2948444T3 (enExample)
IL (3) IL318963A (enExample)
MX (2) MX394051B (enExample)
NZ (1) NZ744323A (enExample)
PH (1) PH12018501279A1 (enExample)
RU (2) RU2737089C2 (enExample)
SG (1) SG11201805149XA (enExample)
WO (1) WO2017103671A1 (enExample)
ZA (2) ZA201804779B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CN105899485B (zh) 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN113896628A (zh) 2015-05-13 2022-01-07 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
EP3861995A1 (en) 2015-07-21 2021-08-11 Affimune Limited Compositions comprising 15-hepe for use in treating or preventing neurologic disease
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
CN113116878A (zh) * 2020-01-10 2021-07-16 南京大学 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11622495B2 (en) 2021-06-01 2023-04-11 Gint Co., Ltd. Method of automatically combining farm vehicle and work machine and farm vehicle
CN113855659B (zh) * 2021-11-24 2022-12-23 中国人民解放军东部战区总医院 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
BR9405620A (pt) 1993-10-01 1999-09-08 Scherer Corp R P Cápsula de gelatina contendo fragr‰ncia, e, processo para sua preparação
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
ATE504557T1 (de) 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20020198177A1 (en) 2001-05-30 2002-12-26 Horrobin David Frederick Coenzyme Q and EPA
WO2004048497A1 (ja) 2002-11-22 2004-06-10 Nippon Suisan Kaisha, Ltd. 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
WO2005063231A2 (en) 2003-12-31 2005-07-14 Igennus Limited Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
CA2572344A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5504405B2 (ja) * 2005-06-10 2014-05-28 国立大学法人山口大学 血管病予防に効果を有する食品組成物
WO2008021192A2 (en) 2006-08-08 2008-02-21 Lipomics Technologies, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
US20110105510A1 (en) 2008-06-17 2011-05-05 Hiroshi Ishikawa Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP2433630A4 (en) * 2009-05-22 2014-01-08 Mochida Pharm Co Ltd SELF-EMULSIFIABLE COMPOSITION OF FATTY ACID 3
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
SG11201401629XA (en) 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2015500639A (ja) 2011-11-29 2015-01-08 ディグニティ サイエンシス リミテッド ２０−炭素脂肪酸を含む組成物ならびにその製造方法および使用方法
CN104321055A (zh) 2012-01-06 2015-01-28 翁特拉制药公司 游离酸形式的ω-3多不饱和脂肪酸的富含dpa组合物
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
IN2014DN08449A (enExample) * 2012-03-30 2015-05-08 Sancilio & Company Inc
US20150079164A1 (en) 2012-04-04 2015-03-19 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
EP4205546A1 (en) * 2012-05-10 2023-07-05 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
ES2841344T3 (es) * 2013-07-18 2021-07-08 Mochida Pharm Co Ltd Composición autoemulsionante de ácidos grasos omega-3
CN105899485B (zh) * 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
US20150196521A1 (en) * 2014-01-10 2015-07-16 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN113893240A (zh) * 2015-01-16 2022-01-07 艾菲穆恩有限公司 包含15-hepe的组合物和其使用方法
CN113896628A (zh) 2015-05-13 2022-01-07 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
EP3861995A1 (en) * 2015-07-21 2021-08-11 Affimune Limited Compositions comprising 15-hepe for use in treating or preventing neurologic disease
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Also Published As

Publication number Publication date
ZA202104969B (en) 2023-01-25
PH12018501279A1 (en) 2019-01-28
US20170172965A1 (en) 2017-06-22
NZ783466A (en) 2025-05-30
US20180104207A1 (en) 2018-04-19
CN113230244A (zh) 2021-08-10
KR20230047501A (ko) 2023-04-07
MX2018007390A (es) 2018-11-09
RU2020137883A (ru) 2020-12-03
RU2737089C2 (ru) 2020-11-24
RU2018126361A3 (enExample) 2020-01-22
US20230106655A1 (en) 2023-04-06
NZ766360A (en) 2025-05-30
AU2022291628B2 (en) 2025-04-03
AR134220A2 (es) 2025-12-10
US9855238B2 (en) 2018-01-02
JP2020063259A (ja) 2020-04-23
KR20240052856A (ko) 2024-04-23
AU2022291628A1 (en) 2023-02-02
AR107143A1 (es) 2018-03-28
BR122023026625A2 (pt) 2024-01-16
US10231945B2 (en) 2019-03-19
CA3008774C (en) 2021-10-12
KR20200055154A (ko) 2020-05-20
AU2016370626A1 (en) 2018-08-02
MX2021000773A (es) 2022-07-19
SG11201805149XA (en) 2018-07-30
AU2025201593A1 (en) 2025-03-20
AU2016370626B2 (en) 2020-08-20
KR20180094516A (ko) 2018-08-23
RU2018126361A (ru) 2020-01-22
JP2018537513A (ja) 2018-12-20
JP2023153863A (ja) 2023-10-18
CA3008774A1 (en) 2017-06-22
BR112018012313A2 (pt) 2018-12-04
WO2017103671A1 (en) 2017-06-22
EP4218736A2 (en) 2023-08-02
EP4218736A3 (en) 2023-10-18
EP3389647A1 (en) 2018-10-24
ZA201804779B (en) 2019-09-25
US20190224154A1 (en) 2019-07-25
MX394051B (es) 2025-03-24
US12274685B2 (en) 2025-04-15
US20250281442A1 (en) 2025-09-11
JP2021178840A (ja) 2021-11-18
IL318963A (en) 2025-04-01
ES2948444T3 (es) 2023-09-12
EP3389647B1 (en) 2023-04-05
CN108697680A (zh) 2018-10-23
KR20250130433A (ko) 2025-09-01
IL294736A (en) 2022-09-01
AU2020267224B2 (en) 2022-09-29
KR20220038818A (ko) 2022-03-29
AU2020267224A1 (en) 2020-12-10
NZ744323A (en) 2020-08-28
IL259846A (en) 2018-07-31
MX379262B (es) 2025-03-10

Similar Documents

Publication Publication Date Title
US12274685B2 (en) Compositions comprising 15-HEPE and methods of using the same
CA2897343C (en) Compositions comprising 15-hepe and use thereof for treating a fatty liver disorder
US20190216761A1 (en) Compositions comprising 15-hepe and methods of using the same
BR112018012313B1 (pt) Uso de ácido 15-hidroxieicosapentaenoico ou de um derivado farmaceuticamente aceitável do mesmo para inibir ou aliviar uma doença selecionada dentre artrite, doença de huntington, sensibilidade à insulina comprometida, psoríase, câncer de pele, diferenciação de adipócitos, dor e obesidade

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

EEER Examination request

Effective date: 20211213

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250512

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250530

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250530